Skip To Main Content
Sara Lonardi on Muck Rack

Sara Lonardi

As seen in: Nature, Wiley Online Library, The Oncologist, Frontiers, MDPI, Cell Press, The Lancet, Journal of Clinical Oncology, Texas Medical Center, Future Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sara

Contact Sara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

|
By Joan Choo, Joseph J. Zhao, Mai Chan Lau, Alessandra Raimondi, Sruthi Ranganathan, Kexin Zhu, Chong Boon Teo, Khi Yung Fong, Jia-Ying Joey Lee, Lit-Hsin Loo, Paolo Manca, Federica Morano, Michele Prisciandaro, Giovanni Randon, Guido Leoni, Elisa Scarselli, Sara Lonardi, Chiara Cremolini, Federica Marmorino, Felicia Wee, Craig Joseph, Akhila Balachander, You Yi Hwang, Laurent Renia, David Tan, Joe Yeong, Raghav Sundar, Filippo Pietrantonio, Willa Wen-You Yim, Hui Xian Chin, Camilla Damonte, Elisa Micarelli, Zhen Wei Neo, Diana GS Lim, Subhra Kumar Biswas
| Nature Verified
Abstract Microsatellite-stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI). The MAYA trial used temozolomide (TMZ) in MGMT-silenced MSS mCRC, hypothesizing that TMZ-induced hypermutation could sensitize tumors to ICI; the primary endpoint was met, showing durable responses with TMZ plus ipilimumab and nivolumab.
Open in Who Shared Issue with article?

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

|
By Angela Damato, Riziero Esposito Abate, Daniela Frezzetti, Dario Righelli, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Filippo Pietrantonio, Giuseppe Tonini, Tiziana Pia Latiano, Roberto Bordonaro, Gerardo Rosati, Elisa Giommoni, Francesco Iachetta, Evaristo Maiello, Sara Lonardi, Alessandra Romagnani, Giuseppe Maglietta, Antonella De Luca, Nicola Normanno, Carmine Pinto, Simona Tessitore, Monica Rosaria Maiello, Mario Larocca
| Nature Verified
Abstract Immunotherapy achieved remarkable results in patients with deficient mismatch repair (dMMR)/microsatellite instable (MSI) metastatic colorectal carcinoma (mCRC). However, its efficacy in proficient MMR (pMMR)/microsatellite stable (MSS) mCRC remains limited. In the phase II NIVACOR trial, we evaluated the activity and safety of FOLFOXIRI/bevacizumab plus nivolumab as first-line therapy in patients with RAS/BRAF-mutated mCRC (NCT04072198).
Open in Who Shared Issue with article?

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

|
By Kohei Shitara, Hirokazu Shoji, Nicola Fazio, Sara Lonardi, Keun-Wook Lee, Li-Yuan Bai, Kensei Yamaguchi, Jean-Philippe Metges, Gianluca Masi, Denis Smith, Tae-Yong Kim, Maria Matsangou, Jason D. Hill, Abraham Guerrero González Verified, Xuewei Wang, Aziz Zaanan, Samuel J. Klempner, Archita Shrivastava, Miaomai Zhou
| Nature Verified
Abstract There is an unmet need for effective and safe treatments for patients with metastatic gastric/gastroesophageal junction (mG/GEJ) adenocarcinoma. Targeting claudin 18 isoform 2 (CLDN18.2) and programmed death ligand 1 (PD-L1), represents a promising strategy. Zolbetuximab, a CLDN18.2-targeting antibody, plus chemotherapy improved survival outcomes in patients with CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative mG/GEJ adenocarcinoma.
Open in Who Shared Issue with article?
See all 52 licensed articles (56 Total)